Non-small cell lung cancer · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Entrectinib monotherapy Variant #01 | ROS1 | R 2 013 430 | 28d | — | — | — | — | — |
Crizotinib monotherapy Variant #01 | ROS1 | R 119 525 | 28d | 11.1 mo | — | 13 | R 1 553 824 PFS proxy | 12 |
Ceritinib monotherapy Variant #01 | ROS1 | R 35 198 | 28d | 11.0 mo | — | 12 | R 422 372 PFS proxy | 2 |
Repotrectinib monotherapy Variant #01 Partial | ROS1 | — | 28d | — | — | — | — | — |
4 of 4 regimens shown